董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Someit Sidhu | 男 | Director | 37 | 8.88万 | 627.10 | 2026-02-21 |
| Amit D. Munshi | -- | Chairman of the Board | -- | 12.11万 | 179.29 | 2026-02-21 |
| Jennifer Ann Jarrett | -- | Independent Director | -- | 9.26万 | 18.60 | 2026-02-21 |
| Sandeep C. Kulkarni | -- | Chief Executive Officer and Director | -- | 9.77万 | 72.14 | 2026-02-21 |
| Daniel Becker | -- | Independent Director | -- | 7.34万 | 未持股 | 2026-02-21 |
| Parvinder Thiara | 男 | Director | -- | 2.18万 | 17.81 | 2026-02-21 |
| Mark Eisner | 男 | Director | 61 | 未披露 | 0.95 | 2026-02-21 |
| Ajay Nirula | 男 | Director | 58 | 未披露 | 0.95 | 2026-02-21 |
| Steven Schoch | 男 | Independent Director | 67 | 9.81万 | 18.60 | 2026-02-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric Hyllengren | 男 | Chief Financial Officer | 51 | 104.85万 | 未持股 | 2026-02-21 |
| Kimberly Ann Davis | -- | Chief Operating Officer, Secretary and Chief Legal Officer | -- | 128.13万 | 未持股 | 2026-02-21 |
| Kiran Nistala | -- | Chief Medical Officer and Head, Development | -- | 102.26万 | 47.12 | 2026-02-21 |
| Gary Whale | -- | Chief Technology Officer | -- | 未披露 | 未持股 | 2026-02-21 |
| Sandeep C. Kulkarni | -- | Chief Executive Officer and Director | -- | 9.77万 | 72.14 | 2026-02-21 |
董事简历
中英对照 | 中文 | 英文- Someit Sidhu
-
Someit Sidhu担任Jatt III Acquisition Corp的董事长、首席执行官兼董事。Sidhu博士拥有涵盖生命科学行业各种主题的广泛专业知识，是该行业的战略顾问和连续生物技术企业家。Sidhu博士是Khanda Therapeutics的创始人，自2025年12月起担任其首席执行官和董事。Sidhu博士还自2026年1月成立以来一直担任JATT II Acquisition Corp的董事长、首席执行官和董事，并自2023年3月与Zura Bio的业务合并完成以来一直担任JATT Acquisition Corp的首席执行官和董事。2023年3月至2024年4月，Sidhu博士担任Zura Bio首席执行官兼董事，此后继续担任Zura Bio董事至2026年5月。Sidhu博士还是Izana Bioscience的联合创始人，并从2017年11月起担任该公司的首席执行官，直到2020年6月该公司最终被出售给Roivant。他还是Pathios Therapeutics和Akaza Bioscience的联合创始人，并在2019年至2021年期间担任其首席执行官。在这些公司之前，Sidhu博士在麦肯锡公司担任管理顾问，为许多大型国际制药公司提供咨询服务，在那里他主要专注于医药研发和投资组合战略。Sidhu博士还自2024年9月起担任GSN Estate董事，自2016年5月起担任Invictus Bioscience董事。Sidhu博士在牛津医学院毕业后，在心脏病学和普外科期间获得了医疗经验，在那里他是Magdalen学院的高级麦金农学者。Sidhu在生命科学行业的丰富运营和投资经验，赋予了他担任董事的资格、属性和技能。
Someit Sidhu serves as Jatt Iii Acquisition Corp's Chairman, Chief Executive Officer and Director. Dr. Sidhu has broad expertise covering various topics in the life sciences industry, and is a strategy consultant and serial biotech entrepreneur in the industry. Dr. Sidhu is the founder of Khanda Therapeutics, and has served as its CEO and director since December 2025. Dr. Sidhu has also served as Chairman, CEO and director of JATT II Acquisition Corp since its inception in January 2026, and as CEO and a director of JATT Acquisition Corp from its inception until the closing of its business combination with Zura Bio in March 2023. From March 2023 to April 2024, Dr. Sidhu served as the CEO and director of Zura Bio, and since continued to serve as director of Zura Bio until May 2026. Dr. Sidhu was also a co founder of Izana Bioscience and served as its CEO from November 2017 until its eventual sale to Roivant in June 2020. He is also Co founder of Pathios Therapeutics and Akaza Bioscience and has served as its CEO from 2019 to 2021. Prior to these companies, Dr. Sidhu advised many large international pharmaceutical companies as a management consultant at McKinsey & Co, where he primarily focused on Pharmaceutical R&D and Portfolio Strategy. Dr. Sidhu has also been serving as director of GSN Estate since September 2024 and as director of Invictus Bioscience since May 2016. Dr. Sidhu gained medical experience during his time in Cardiology and General Surgery after graduating from the Oxford Medical School where he was a Senior Mackinnon Scholar at Magdalen College. Sidhu's extensive operational and investment experience in the life sciences industry gives him the qualifications, attributes and skills to serve as a director. - Someit Sidhu担任Jatt III Acquisition Corp的董事长、首席执行官兼董事。Sidhu博士拥有涵盖生命科学行业各种主题的广泛专业知识，是该行业的战略顾问和连续生物技术企业家。Sidhu博士是Khanda Therapeutics的创始人，自2025年12月起担任其首席执行官和董事。Sidhu博士还自2026年1月成立以来一直担任JATT II Acquisition Corp的董事长、首席执行官和董事，并自2023年3月与Zura Bio的业务合并完成以来一直担任JATT Acquisition Corp的首席执行官和董事。2023年3月至2024年4月，Sidhu博士担任Zura Bio首席执行官兼董事，此后继续担任Zura Bio董事至2026年5月。Sidhu博士还是Izana Bioscience的联合创始人，并从2017年11月起担任该公司的首席执行官，直到2020年6月该公司最终被出售给Roivant。他还是Pathios Therapeutics和Akaza Bioscience的联合创始人，并在2019年至2021年期间担任其首席执行官。在这些公司之前，Sidhu博士在麦肯锡公司担任管理顾问，为许多大型国际制药公司提供咨询服务，在那里他主要专注于医药研发和投资组合战略。Sidhu博士还自2024年9月起担任GSN Estate董事，自2016年5月起担任Invictus Bioscience董事。Sidhu博士在牛津医学院毕业后，在心脏病学和普外科期间获得了医疗经验，在那里他是Magdalen学院的高级麦金农学者。Sidhu在生命科学行业的丰富运营和投资经验，赋予了他担任董事的资格、属性和技能。
- Someit Sidhu serves as Jatt Iii Acquisition Corp's Chairman, Chief Executive Officer and Director. Dr. Sidhu has broad expertise covering various topics in the life sciences industry, and is a strategy consultant and serial biotech entrepreneur in the industry. Dr. Sidhu is the founder of Khanda Therapeutics, and has served as its CEO and director since December 2025. Dr. Sidhu has also served as Chairman, CEO and director of JATT II Acquisition Corp since its inception in January 2026, and as CEO and a director of JATT Acquisition Corp from its inception until the closing of its business combination with Zura Bio in March 2023. From March 2023 to April 2024, Dr. Sidhu served as the CEO and director of Zura Bio, and since continued to serve as director of Zura Bio until May 2026. Dr. Sidhu was also a co founder of Izana Bioscience and served as its CEO from November 2017 until its eventual sale to Roivant in June 2020. He is also Co founder of Pathios Therapeutics and Akaza Bioscience and has served as its CEO from 2019 to 2021. Prior to these companies, Dr. Sidhu advised many large international pharmaceutical companies as a management consultant at McKinsey & Co, where he primarily focused on Pharmaceutical R&D and Portfolio Strategy. Dr. Sidhu has also been serving as director of GSN Estate since September 2024 and as director of Invictus Bioscience since May 2016. Dr. Sidhu gained medical experience during his time in Cardiology and General Surgery after graduating from the Oxford Medical School where he was a Senior Mackinnon Scholar at Magdalen College. Sidhu's extensive operational and investment experience in the life sciences industry gives him the qualifications, attributes and skills to serve as a director.
- Amit D. Munshi
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Jennifer Ann Jarrett
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Sandeep C. Kulkarni
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Daniel Becker
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Parvinder Thiara
-
Parvinder Thiara，于2017年1月创立Athanor Capital，是一家总部位于纽约的对冲基金管理公司，目前担任其首席投资官。Thiara先生还担任Zura Bio Limited的董事会成员。此前，Thiara先生曾在D.E. Shaw & Co.担任多个职务，包括最近担任高级副总裁。Thiara先生作为罗德学者获得了哈佛学院化学学士学位和牛津大学理论化学硕士学位。
Parvinder Thiara,founded Athanor Capital in January 2017, a New York-based hedge fund manager, and currently serves as its Chief Investment Officer. Mr. Thiara also serves as a member of the board of directors of Zura Bio Limited. Previously, Mr. Thiara held various roles at D.E. Shaw & Co., including most recently as a Senior Vice President. Mr. Thiara earned a B.A. degree in Chemistry from Harvard College and an M.Sc. degree in Theoretical Chemistry from Oxford University as a Rhodes Scholar. - Parvinder Thiara，于2017年1月创立Athanor Capital，是一家总部位于纽约的对冲基金管理公司，目前担任其首席投资官。Thiara先生还担任Zura Bio Limited的董事会成员。此前，Thiara先生曾在D.E. Shaw & Co.担任多个职务，包括最近担任高级副总裁。Thiara先生作为罗德学者获得了哈佛学院化学学士学位和牛津大学理论化学硕士学位。
- Parvinder Thiara,founded Athanor Capital in January 2017, a New York-based hedge fund manager, and currently serves as its Chief Investment Officer. Mr. Thiara also serves as a member of the board of directors of Zura Bio Limited. Previously, Mr. Thiara held various roles at D.E. Shaw & Co., including most recently as a Senior Vice President. Mr. Thiara earned a B.A. degree in Chemistry from Harvard College and an M.Sc. degree in Theoretical Chemistry from Oxford University as a Rhodes Scholar.
- Mark Eisner
-
Mark Eisner于2023年9月至2024年6月在私营临床阶段生物技术公司Sonoma Biotherapeutics，Inc.担任首席医疗官，领导所有开发职能，包括生物识别、监管、临床科学、临床运营、药物安全和药理学。2020年至2023年9月，他在生物制药公司珐博进公司（nka Kyntra Bio，Inc.）（纳斯达克：KYNB）担任执行副总裁兼首席医疗官，领导所有开发职能，包括担任中国临床开发和临床运营主管。在加入珐博进之前，Eisner博士在罗氏集团成员基因泰克工作了近11年，担任的职位责任越来越大，包括2018年至2020年的高级副总裁、免疫学、感染病和眼科产品开发全球主管，并负责许多产品的后期临床开发。在进入工业之前，艾斯纳博士是加州大学旧金山分校的医学和麻醉学教授。艾斯纳博士在斯坦福大学完成了人类生物学的A.B.学位，并在宾夕法尼亚大学医学院完成了医学博士学位。他还拥有加州大学伯克利分校公共卫生学院流行病学硕士学位。
Mark Eisner served as Chief Medical Officer at Sonoma Biotherapeutics, Inc., a private clinical stage biotechnology company, from September 2023 to June 2024, where he led all development functions, which included Biometrics, Regulatory, Clinical Science, Clinical Operations, Drug Safety and Pharmacology. From 2020 to September 2023, he served as Executive Vice President, Chief Medical Officer at FibroGen, Inc. (nka Kyntra Bio, Inc.) (Nasdaq: KYNB), a biopharmaceutical company, where he led all development functions, which included being the Head of China Clinical Development and Clinical Operations. Prior to FibroGen, Dr. Eisner spent nearly 11 years at Genentech, Inc., a member of the Roche Group, holding positions of increasing responsibility, including Senior Vice President, Global Head of Product Development for Immunology, Infectio Disease and Ophthalmology from 2018 to 2020, and was accountable for late stage clinical development of many products. Prior to entering industry, Dr. Eisner was Professor of Medicine and Anesthesia at the University of California, San Francisco. Dr. Eisner completed his A.B. degree in human biology at Stanford University and his M.D. degree at the University of Pennsylvania School of Medicine. He also holds an M.P.H. focused on epidemiology from the University of California, Berkeley, School of Public Health. - Mark Eisner于2023年9月至2024年6月在私营临床阶段生物技术公司Sonoma Biotherapeutics，Inc.担任首席医疗官，领导所有开发职能，包括生物识别、监管、临床科学、临床运营、药物安全和药理学。2020年至2023年9月，他在生物制药公司珐博进公司（nka Kyntra Bio，Inc.）（纳斯达克：KYNB）担任执行副总裁兼首席医疗官，领导所有开发职能，包括担任中国临床开发和临床运营主管。在加入珐博进之前，Eisner博士在罗氏集团成员基因泰克工作了近11年，担任的职位责任越来越大，包括2018年至2020年的高级副总裁、免疫学、感染病和眼科产品开发全球主管，并负责许多产品的后期临床开发。在进入工业之前，艾斯纳博士是加州大学旧金山分校的医学和麻醉学教授。艾斯纳博士在斯坦福大学完成了人类生物学的A.B.学位，并在宾夕法尼亚大学医学院完成了医学博士学位。他还拥有加州大学伯克利分校公共卫生学院流行病学硕士学位。
- Mark Eisner served as Chief Medical Officer at Sonoma Biotherapeutics, Inc., a private clinical stage biotechnology company, from September 2023 to June 2024, where he led all development functions, which included Biometrics, Regulatory, Clinical Science, Clinical Operations, Drug Safety and Pharmacology. From 2020 to September 2023, he served as Executive Vice President, Chief Medical Officer at FibroGen, Inc. (nka Kyntra Bio, Inc.) (Nasdaq: KYNB), a biopharmaceutical company, where he led all development functions, which included being the Head of China Clinical Development and Clinical Operations. Prior to FibroGen, Dr. Eisner spent nearly 11 years at Genentech, Inc., a member of the Roche Group, holding positions of increasing responsibility, including Senior Vice President, Global Head of Product Development for Immunology, Infectio Disease and Ophthalmology from 2018 to 2020, and was accountable for late stage clinical development of many products. Prior to entering industry, Dr. Eisner was Professor of Medicine and Anesthesia at the University of California, San Francisco. Dr. Eisner completed his A.B. degree in human biology at Stanford University and his M.D. degree at the University of Pennsylvania School of Medicine. He also holds an M.P.H. focused on epidemiology from the University of California, Berkeley, School of Public Health.
- Ajay Nirula
-
Ajay Nirula自2024年4月起担任Recludix Pharma执行副总裁兼研发主管。Previoly，Nirula博士于2022年10月至2024年4月期间担任礼来公司（“礼来”）（纽约证券交易所代码：LLY）高级副总裁兼免疫治疗主管和位于圣地亚哥的礼来生物技术中心现场主管，并于2015年至2022年10月期间担任副总裁。在加入礼来公司之前，Nirula博士曾在安进公司和渤健 Idec MA Inc.担任领导职务，并参与了多个研究计划和监管备案，涉及类风湿性关节炎、系统性乳头状红斑、多发性硬化症、银屑病和血管炎等疾病。Nirula博士的职业生涯始于默沙东公司，该公司领导心血管疾病和炎症分子的早期临床开发。Nirula博士在加州大学伯克利分校完成了分子生物学本科学位，在加州大学洛杉矶分校医学院获得了医学博士学位，在得克萨斯大学南斯滕医学院获得了博士学位。他获得了内科和风湿病学的董事会认证，随后加入了加州大学旧金山分校医学中心风湿病学部门的教师。
Ajay Nirula has served as Recludix Pharma's Executive Vice President and Head of Research and Development at since April 2024. Previoly, Dr. Nirula served as Eli Lilly and Company's ("Lilly") (NYSE: LLY) Senior Vice President and Immunology Therapeutic Head and the site head for Lilly Biotechnology Center in San Diego from October 2022 through April 2024 and Vice President from 2015 through October 2022. Prior to joining Lilly, Dr. Nirula held leadership positions at Amgen Inc. and Biogen Idec MA Inc. and was involved in several research programs and regulatory filings spanning diseases such as rheumatoid arthritis, systemic lup erythematos, multiple sclerosis, psoriasis and vasculitis. Dr. Nirula began his career at Merck &Co., Inc. leading early clinical development of molecules in cardiovascular disease and inflammation. Dr. Nirula completed his undergraduate degree in molecular biology at University of California, Berkeley, his M.D. degree from UCLA School of Medicine, and his Ph.D. from the University of Texas Southstern Medical School. He obtained board certification in Internal Medicine and Rheumatology and subsequently joined the faculty in the Division of Rheumatology at UCSF Medical Center. - Ajay Nirula自2024年4月起担任Recludix Pharma执行副总裁兼研发主管。Previoly，Nirula博士于2022年10月至2024年4月期间担任礼来公司（“礼来”）（纽约证券交易所代码：LLY）高级副总裁兼免疫治疗主管和位于圣地亚哥的礼来生物技术中心现场主管，并于2015年至2022年10月期间担任副总裁。在加入礼来公司之前，Nirula博士曾在安进公司和渤健 Idec MA Inc.担任领导职务，并参与了多个研究计划和监管备案，涉及类风湿性关节炎、系统性乳头状红斑、多发性硬化症、银屑病和血管炎等疾病。Nirula博士的职业生涯始于默沙东公司，该公司领导心血管疾病和炎症分子的早期临床开发。Nirula博士在加州大学伯克利分校完成了分子生物学本科学位，在加州大学洛杉矶分校医学院获得了医学博士学位，在得克萨斯大学南斯滕医学院获得了博士学位。他获得了内科和风湿病学的董事会认证，随后加入了加州大学旧金山分校医学中心风湿病学部门的教师。
- Ajay Nirula has served as Recludix Pharma's Executive Vice President and Head of Research and Development at since April 2024. Previoly, Dr. Nirula served as Eli Lilly and Company's ("Lilly") (NYSE: LLY) Senior Vice President and Immunology Therapeutic Head and the site head for Lilly Biotechnology Center in San Diego from October 2022 through April 2024 and Vice President from 2015 through October 2022. Prior to joining Lilly, Dr. Nirula held leadership positions at Amgen Inc. and Biogen Idec MA Inc. and was involved in several research programs and regulatory filings spanning diseases such as rheumatoid arthritis, systemic lup erythematos, multiple sclerosis, psoriasis and vasculitis. Dr. Nirula began his career at Merck &Co., Inc. leading early clinical development of molecules in cardiovascular disease and inflammation. Dr. Nirula completed his undergraduate degree in molecular biology at University of California, Berkeley, his M.D. degree from UCLA School of Medicine, and his Ph.D. from the University of Texas Southstern Medical School. He obtained board certification in Internal Medicine and Rheumatology and subsequently joined the faculty in the Division of Rheumatology at UCSF Medical Center.
- Steven Schoch
-
Steven Schoch，自2023年3月起担任Zura董事，自2023年1月起担任Legacy Zura董事。他曾于2021年6月担任Arena董事会成员并担任审计委员会主席，直到该公司于2022年3月被辉瑞收购。Schoch先生目前担任RefleXion的首席财务官，自2024年11月起担任该职位。在加入RefleXion之前，Schoch先生于2022年9月至2024年11月担任FLYR Labs的首席运营官和首席财务官，并于2018年4月至2022年9月担任23andMe，Inc.的首席财务官。Schoch先生于2012年3月至2017年1月担任Miramax Films NY，LLC的首席执行官，并于2011年1月至2017年1月担任Miramax的首席财务官，任职时间重叠。从2001年到2010年，Schoch先生曾在安进公司担任多个高级财务职务，包括公司控制人和部门财务副总裁。1999年1月至2001年4月担任易玩具股份有限公司执行副总裁兼首席财务官。在加入eToys，Inc.之前，Schoch先生曾在媒体行业担任过多个金融职位，包括在华特迪士尼公司和时代镜报公司任职。Schoch先生拥有塔夫茨大学土木工程学士学位和达特茅斯学院塔克工商管理学院工商管理硕士学位。
Steven Schoch,has served as a director of Zura since March 2023 and served as a director of Legacy Zura since January 2023. He served as a member of the board of directors of Arena and chaired the audit committee from June 2021 until the company was acquired by Pfizer in March 2022. Mr. Schoch currently serves as Chief Financial Officer of RefleXion, a position he has held since November 2024. Prior to joining RefleXion, Mr. Schoch served as Chief Operating Officer and Chief Financial Officer of FLYR Labs from September 2022 to November 2024 and Chief Financial Officer at 23andMe, Inc. from April 2018 to September 2022. Mr. Schoch served as the Chief Executive Officer of Miramax Films NY, LLC from March 2012 to January 2017, with overlapping service as Miramax's Chief Financial Officer from January 2011 to January 2017. From 2001 to 2010, Mr. Schoch held various senior financial positions at Amgen, Inc., including Corporate Controller and divisional Financial Vice President. He served as the Executive Vice President and Chief Financial Officer of eToys, Inc. from January 1999 to April 2001. Prior to eToys, Inc., Mr. Schoch held a variety of financial positions in the media industry, including at The Walt Disney Company and the Times Mirror Company. Mr. Schoch holds a B.S. in Civil Engineering degree from Tufts University and a M.B.A. degree from the Tuck School of Business Administration, Dartmouth College. - Steven Schoch，自2023年3月起担任Zura董事，自2023年1月起担任Legacy Zura董事。他曾于2021年6月担任Arena董事会成员并担任审计委员会主席，直到该公司于2022年3月被辉瑞收购。Schoch先生目前担任RefleXion的首席财务官，自2024年11月起担任该职位。在加入RefleXion之前，Schoch先生于2022年9月至2024年11月担任FLYR Labs的首席运营官和首席财务官，并于2018年4月至2022年9月担任23andMe，Inc.的首席财务官。Schoch先生于2012年3月至2017年1月担任Miramax Films NY，LLC的首席执行官，并于2011年1月至2017年1月担任Miramax的首席财务官，任职时间重叠。从2001年到2010年，Schoch先生曾在安进公司担任多个高级财务职务，包括公司控制人和部门财务副总裁。1999年1月至2001年4月担任易玩具股份有限公司执行副总裁兼首席财务官。在加入eToys，Inc.之前，Schoch先生曾在媒体行业担任过多个金融职位，包括在华特迪士尼公司和时代镜报公司任职。Schoch先生拥有塔夫茨大学土木工程学士学位和达特茅斯学院塔克工商管理学院工商管理硕士学位。
- Steven Schoch,has served as a director of Zura since March 2023 and served as a director of Legacy Zura since January 2023. He served as a member of the board of directors of Arena and chaired the audit committee from June 2021 until the company was acquired by Pfizer in March 2022. Mr. Schoch currently serves as Chief Financial Officer of RefleXion, a position he has held since November 2024. Prior to joining RefleXion, Mr. Schoch served as Chief Operating Officer and Chief Financial Officer of FLYR Labs from September 2022 to November 2024 and Chief Financial Officer at 23andMe, Inc. from April 2018 to September 2022. Mr. Schoch served as the Chief Executive Officer of Miramax Films NY, LLC from March 2012 to January 2017, with overlapping service as Miramax's Chief Financial Officer from January 2011 to January 2017. From 2001 to 2010, Mr. Schoch held various senior financial positions at Amgen, Inc., including Corporate Controller and divisional Financial Vice President. He served as the Executive Vice President and Chief Financial Officer of eToys, Inc. from January 1999 to April 2001. Prior to eToys, Inc., Mr. Schoch held a variety of financial positions in the media industry, including at The Walt Disney Company and the Times Mirror Company. Mr. Schoch holds a B.S. in Civil Engineering degree from Tufts University and a M.B.A. degree from the Tuck School of Business Administration, Dartmouth College.
高管简历
中英对照 | 中文 | 英文- Eric Hyllengren
Eric Hyllengren，最近的一次任职是Atara Biotherapeutics, Inc.（纳斯达克：ATRA）（“Atara”）的首席财务官兼首席运营官，分别自2023年4月和2024年10月起，此前曾于2018年8月至2023年4月担任Atara的财务副总裁。在加入Atara之前，Hyllengren先生于2003年7月至2018年8月在安进公司（纳斯达克：AMGN）（“安进”）担任过各种领导职务，最近的一次是在2017年11月至2018年8月担任安进的业务发展执行董事和联盟管理负责人。Hyllengren先生拥有圣母大学金融学学士学位和俄语学士学位，以及西北大学家乐氏管理学院金融学硕士学位。
Eric Hyllengren,was most recently Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara"), since April 2023 and October 2024, respectively, and was previously Atara's Vice President of Finance from August 2018 to April 2023. Prior to joining Atara, Mr. Hyllengren held various leadership roles at Amgen Inc. (Nasdaq: AMGN) ("Amgen") from July 2003 to August 2018 and, most recently, was Amgen's Executive Director of Business Development and Head of Alliance Management from November 2017 to August 2018. Mr. Hyllengren holds a B.B.A. in Finance and Russian from the University of Notre Dame and an M.B.A. in Finance from the Kellogg School of Management at Northwestern University.- Eric Hyllengren，最近的一次任职是Atara Biotherapeutics, Inc.（纳斯达克：ATRA）（“Atara”）的首席财务官兼首席运营官，分别自2023年4月和2024年10月起，此前曾于2018年8月至2023年4月担任Atara的财务副总裁。在加入Atara之前，Hyllengren先生于2003年7月至2018年8月在安进公司（纳斯达克：AMGN）（“安进”）担任过各种领导职务，最近的一次是在2017年11月至2018年8月担任安进的业务发展执行董事和联盟管理负责人。Hyllengren先生拥有圣母大学金融学学士学位和俄语学士学位，以及西北大学家乐氏管理学院金融学硕士学位。
- Eric Hyllengren,was most recently Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara"), since April 2023 and October 2024, respectively, and was previously Atara's Vice President of Finance from August 2018 to April 2023. Prior to joining Atara, Mr. Hyllengren held various leadership roles at Amgen Inc. (Nasdaq: AMGN) ("Amgen") from July 2003 to August 2018 and, most recently, was Amgen's Executive Director of Business Development and Head of Alliance Management from November 2017 to August 2018. Mr. Hyllengren holds a B.B.A. in Finance and Russian from the University of Notre Dame and an M.B.A. in Finance from the Kellogg School of Management at Northwestern University.
- Kimberly Ann Davis
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Kiran Nistala
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Gary Whale
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Sandeep C. Kulkarni
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介